Venetoclax: Potential Use in Multiple Myeloma A. Keith Stewart, MB, ChB; Sagar Lonial, MD, FACP; Thomas Martin, MD; Edward A. Stadtmauer, MD; Amrita Krishnan, MD, FACP; and Ajai Chari, MD, consider venetoclax’s role in the treatment of multiple myeloma and whether its potential is limited to patients with t(11;14) as a biomarker.

ASCO and EHA Overview of Top Multiple Myeloma Abstracts and Posters In this video, IMF Chief Medical Officer Dr. Joseph Mikhael (TGen, City of Hope Cancer Center – Scottsdale, AZ, USA) provides an overview of the top myeloma-related abstracts from the 2021 American Clinical Society of Oncology (ASCO) and 2021 European Hematology Association (EHA) annual […]

non-small cell lung cancer herapeutics market to expand at a healthy CAGR of 12.10% over the period from 2015 to 2023 and reach a value of US$15.1 bn by the end of the forecast period A research study, recently published by Transparency Market Research (TMR), estimates the global non-small cell lung cancer therapeutics market to […]

Member Voice: 'I Had Multiple Myeloma' After constant encouragement from his wife, Danny Webb went to see a doctor about his ongoing back pain. An MRI and biopsy concluded that he had Multiple Myeloma. Multiple Myeloma is a cancer formed by malignant plasma cells. In 2011, there were an estimated 83,367 people living with myeloma […]

Blood Cancer | Types, Latest Treatment Plan, Life Expectancy – Dr.Mangesh P Kamath | Doctors' Circle Dr. Mangesh P Kamath |Appointment booking no: 09353003070 Website: drmangeshkamathcancercare.com Senior Consultant & Medical Director | Medical and HematoOncologist, BMT Physician, Oncology International Clinics, J.P Nagar Bangalore Blood is an organ of the body and it constitutes the RBCs, […]

The Evolving Role of Immune Therapies in Multiple Myeloma Dr. Paul Richardson discusses “The Evolving Role of Immune Therapies: Treatments That Work With Our Own Immune Systems” during the IMF Patient and Family Webinar 2021. This IMF Patient & Family Webinar offers myeloma patients and caregivers up-to-the-minute guidance for staying safe in our COVID-19 world. […]

Edward Cain, multiple myeloma survivor Edward Cain woke up one day not able to get out of bed and with a tremendous pain in his back. Thinking it was spine-related due to playing basketball, he later learned it was because of multiple myeloma. He underwent surgery and started treatment with our world-renowned team of multiple […]

Myeloma Teacher Shares Hope for Multiple Myeloma Patients Multiple Myeloma patient advocate Cindy, better known as the “Myeloma Teacher,” shares her excitement over new treatments for Multiple Myeloma. #ASH20 #ASH2020

Daratumumab Safe in Relapsed/Refractory Multiple Myeloma Patients The anti-CD38 monoclonal antibody daratumumab had a favorable safety profile with manageable infusion-related reactions, according to results from a phase 2 study of multiple myeloma patients who had been treated with three or more prior therapies. Peter M. Voorhees, MD, discusses the results.

Induction Therapy Considerations in Multiple Myeloma Expert perspective regarding optimal durations of induction therapy and the importance of achieving depth of response in multiple myeloma.